Heart health outcomes in adults with type 2 diabetes and artery disease starting oral semaglutide versus other non-insulin diabetes medicines

Semaglutide is associated with a reduction in the risk of major adverse cardiovascular events (MACE) in people with type 2 diabetes (T2D) who are at high risk for these events.

• Clinical trials indicate that semaglutide can lower the incidence of MACE in at-risk individuals with T2D.
• The effects of oral semaglutide on cardiovascular risk in everyday settings remain unclear.
• Further investigation is needed to understand the real-world implications of oral semaglutide on cardiovascular health.

Simplified